IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA)

Historical Holders from Q2 2017 to Q4 2025

Type / Class: Equity / Common Stock
Symbol: IOVA on Nasdaq
Shares outstanding: 334,352,960
Price per share: $2.73
All holders as of 30 Sep 2025: Q3 2025
Total 13F shares as of 30 Sep 2025: 212,916,177
Holdings value: $462,029,911
% of all portfolios: 0%
Share change: -7,193,815
Value change: -$12,410,675
Average buys %: +0%
Average sells %: -0%
Number of holders: 246
Price from insider filings: $2.14

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Significant Owners of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) based on Schedule 13D/G filings

Filer	Ownership	Change %	Holdings Value	Net Change	Nb Shares	Change %	Reporting Name	Report Period
VANGUARD GROUP INC	7.5%		$43,131,532		25,076,472		The Vanguard Group	30 Jun 2025
BlackRock, Inc.	6.4%		$36,645,720		21,305,651		BlackRock, Inc.	30 Jun 2025
PERCEPTIVE ADVISORS LLC	3.8%	-50%	$45,599,285	-$33,120,382	12,808,788	-42%	Perceptive Advisors LLC	31 Mar 2025

As of 30 Sep 2025, IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) has 246 institutional shareholders filing 13F forms. They hold 212,916,177 shares of 334,352,960 outstanding shares (64%) .

Top 25 institutional shareholders own 54% of the company.

Filer	Ownership	Nb Shares	Share Change %	Portfolio %	Holdings Value
MHR FUND MANAGEMENT LLC	8.7%	28,967,103	0%	6.2%	$62,858,614
BlackRock, Inc.	7.8%	25,956,289	+12%	0%	$56,325,148
VANGUARD GROUP INC	7.2%	24,058,983	-4.1%	0%	$52,207,993
STATE STREET CORP	4%	13,309,959	+35%	0%	$28,882,611
Invenomic Capital Management LP	3.2%	10,541,608	+27%	1.2%	$22,875,289
Long Focus Capital Management, LLC	2.7%	9,116,507	-23%	1.2%	$19,782,820
Palo Alto Investors LP	2.3%	7,618,132	+122%	3.1%	$16,531,346
GEODE CAPITAL MANAGEMENT, LLC	2.1%	6,868,303	+11%	0%	$14,905,575
GOLDMAN SACHS GROUP INC	2%	6,575,502	+38%	0%	$14,268,839
BANK OF AMERICA CORP /DE/	1.9%	6,279,230	+56%	0%	$13,625,928
MORGAN STANLEY	1.7%	5,581,563	-13%	0%	$12,111,992
MILLENNIUM MANAGEMENT LLC	1.3%	4,413,451	-53%	0.01%	$9,577,189
CITADEL ADVISORS LLC	1.1%	3,820,364	-7.1%	0.01%	$8,290,189
SUSQUEHANNA INTERNATIONAL GROUP, LLP	0.99%	3,306,516	+60%	0.01%	$7,175,140
PRINCIPAL FINANCIAL GROUP INC	0.9%	3,013,753	-35%	0%	$6,539,845
DIMENSIONAL FUND ADVISORS LP	0.84%	2,822,758	-3.6%	0%	$6,126,547
TWO SIGMA INVESTMENTS, LP	0.82%	2,740,854	-41%	0.01%	$5,947,653
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	0.75%	2,504,542	+31%	0%	$5,434,856
NORTHERN TRUST CORP	0.74%	2,461,073	+16%	0%	$5,340,529
PRICE T ROWE ASSOCIATES INC /MD/	0.62%	2,058,018	-2.7%	0%	$4,467,000
Orion Investment Co	0.55%	1,851,784	-21%	1.3%	$4,018,371
ROYAL BANK OF CANADA	0.47%	1,554,813	-35%	0%	$3,375,000
WELLS FARGO & COMPANY/MN	0.45%	1,517,364	+41%	0%	$3,292,680
B Group, Inc.	0.45%	1,500,000	0%	3.1%	$3,255,000
RICE HALL JAMES & ASSOCIATES, LLC	0.43%	1,451,372	-8.8%	0.17%	$3,149,476

Institutional Holders of IOVANCE BIOTHERAPEUTICS, INC. - Common Stock (IOVA) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price	Investors
2025 Q4	164,139	$443,361	+$127,176			$2.73	5
2025 Q3	212,916,177	$462,029,911	-$12,410,675	$3,644,232	$5,225,205	$2.17	246
2025 Q2	220,039,758	$378,480,610	-$103,966,458	$1,941,880	$1,925,024	$1.72	244
2025 Q1	239,455,648	$797,796,916	-$41,501,290	$5,309,820	$4,484,986	$3.33	292
2024 Q4	241,507,506	$1,786,983,312	+$22,988,107	$25,768,984	$17,831,446	$7.40	294
2024 Q3	235,201,336	$2,210,596,727	+$25,452,589	$15,797,534	$35,379,888	$9.39	280
2024 Q2	232,474,427	$1,864,558,933	+$97,335,567	$13,311,596	$10,168,558	$8.02	287
2024 Q1	217,101,064	$3,216,301,753	+$212,421,390	$23,425,974	$44,458,518	$14.82	266
2023 Q4	207,297,037	$1,685,397,432	-$32,505,370	$13,896,609	$39,245,136	$8.13	233
2023 Q3	213,137,480	$969,776,344	+$6,686,675	$9,433,515	$25,850,825	$4.55	223
2023 Q2	203,959,385	$1,435,734,710	-$789,310	$4,161,563	$6,445,248	$7.04	214
2023 Q1	205,425,383	$1,254,751,936	+$199,378,894	$4,857,130	$4,189,062	$6.11	225
2022 Q4	173,249,347	$1,106,975,435	+$100,178,837	$2,048,643	$3,303,749	$6.39	213
2022 Q3	154,414,415	$1,478,691,442	-$53,630,372	$2,635,000	$14,601,000	$9.58	231
2022 Q2	156,417,705	$1,726,071,008	+$13,073,879	$11,303,568	$21,380,416	$11.04	227
2022 Q1	155,843,237	$2,593,671,140	-$16,926,612	$6,793,000	$33,043,000	$16.65	231
2021 Q4	155,850,778	$2,963,320,040	-$77,138,233	$15,452,000	$70,843,055	$19.09	235
2021 Q3	157,966,360	$3,882,977,675	-$126,474,780	$27,117,000	$38,473,000	$24.66	238
2021 Q2	162,111,422	$4,215,394,735	+$75,696,267	$32,724,710	$84,748,000	$26.02	226
2021 Q1	156,513,608	$4,954,837,773	+$228,194,179	$17,385,000	$35,894,766	$31.66	240
2020 Q4	148,752,147	$6,902,468,525	+$436,980,892	$73,818,000	$107,134,080	$46.40	264
2020 Q3	139,955,271	$4,606,819,956	-$20,115,200	$24,388,000	$52,526,000	$32.92	245
2020 Q2	140,811,545	$3,876,458,222	+$501,586,010	$20,787,000	$39,708,000	$27.45	254
2020 Q1	122,545,305	$3,667,866,974	-$30,050,711	$14,400,000	$59,925,000	$29.94	214
2019 Q4	124,152,367	$3,436,416,158	+$2,487,658	$7,134,000	$42,773,000	$27.68	196
2019 Q3	123,451,560	$2,246,787,056	+$1,725,871	$2,539,000	$21,420,000	$18.20	169
2019 Q2	122,286,530	$2,995,401,566	+$230,321,379	$1,582,000	$19,150,000	$24.52	162
2019 Q1	117,236,707	$1,114,459,029	-$10,984,795	$238,000	$1,014,000	$9.51	147
2018 Q4	118,553,949	$1,048,865,157	+$237,101,241	$420,000	$1,037,000	$8.85	134
2018 Q3	90,396,956	$1,016,473,349	+$78,564,266	$1,413,000	$4,113,000	$11.25	129
2018 Q2	83,236,651	$1,065,503,232	+$54,089,415	$1,659,000	$4,487,000	$12.80	124
2018 Q1	77,770,935	$1,312,527,807	+$341,021,805	$1,311,000	$7,001,000	$16.90	120
2017 Q4	57,639,452	$460,738,120	+$14,620,712	$339,000	$657,000	$8.00	85
2017 Q3	55,295,141	$428,707,093	+$59,837,958	$253,000	$172,000	$7.75	85
2017 Q2	47,622,569	$349,319,767	+$349,310,767	$8,000	$3,255,000	$7.35	82